Pharsight

Ofirmev generic

Ofirmev is an analgesic and antipyretic drug owned by Mallinckrodt Hosp. The active ingredient in Ofirmev is acetaminophen. The drug was first marketed on November 02, 2010. Ofirmev is available in a solution; intravenous dosage form and holds a total of 7 patents.

When will Ofirmev generic be available?

The possibility of a generic version for Ofirmev can be anticipated after March 11, 2032. This because the last patent of Ofirmev, US9399012*PED titled as Reduced dose intravenous acetaminophen, expires on this date, clearing the way for the release of Ofirmev generic.

Ofirmev uses

Ofirmev plays a crucial role in the reduction of fever and the management of pain. It is suitable for managing mild to moderate pain independently or managing moderate to severe pain as an adjunct to opioid analgesics.

Ofirmev patent expiration

Ofirmev holds seven patents, out of which none have been expired yet. The last patent (US9399012*PED) under the title of 'Reduced dose intravenous acetaminophen' is expected to expire on March 11, 2032. Following this, the drug Ofirmev generic can be expected in the market. Below are the details of the patent:

Ofirmev dosage

Want to ask something?